Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes Clinical Trial

Official title:

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01928537
• Other study ID #: Onconova 04-24
• Secondary ID: 2013-001124-19
• Status: Completed
• Phase: Phase 3
• Start date: August 2013
• Est. completion date: June 29, 2017

Study information

• Verified date: July 2018
• Source: Onconova Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: June 29, 2017
• Est. primary completion date: June 29, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of MDS confirmed within 6 weeks prior to Screening according to WHO criteria or French-American-British (FAB) classification.

• MDS classified as follows, according to WHO criteria and FAB classification:

• RAEB-1 (5% to 9% BM blasts)

• RAEB-2 (10% to 19% BM blasts)

• CMML (10% to 20% BM blasts) and white blood cells (WBC) < 13,000/µL

• RAEB-t (20% to 30% BM blasts), meeting the following criteria: WBC < 25,000/µL at study entry; or, Stable White Blood Cell (WBC) at least 4 weeks prior to Screening and not requiring intervention for WBC control with hydroxyurea, chemotherapy, or leukopheresis.

• At least one cytopenia (Absolute Neutrophil Count (ANC) < 1800/µL or Platelet (PLT) count < 100,000/µL or hemoglobin (Hgb) < 10 g/dL).

• Progression (according to 2006 IWG criteria) at any time after initiation of subcutaneous or intravenous azacitidine or decitabine treatment per labeling during the past 2 years, defined as follows:

• For patients with ? 5% BMBL, = 50% increase in BMBL to ? 5% BMBL

• For patients with 5-10% BMBL, = 50% increase in BMBL to ? 10% BMBL

• For patients with 10-20% BMBL, = 50% increase in BMBL to ? 20% BMBL

• For patients with 20-30% BMBL, = 50% increase in BMBL to ? 30% BMBL

• Any of the following: = 50% decrease from maximum remission/response levels in granulocytes or PLT; Decrease in Hgb concentration by = 2 g/dL; or, Transfusion dependence, defined as administration of at least 4 RBC units in the past 8 weeks before Screening (patients must have Hgb values ? 9 g/dL prior to transfusion to be considered), in the absence of another explanation.

• Has failed to respond to, relapsed following, not eligible, or opted not to participate in bone marrow transplantation.

• Off all other treatments for MDS for at least 4 weeks, except for azacitidine or decitabine. Filgrastim (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated.

• No medical need for induction chemotherapy.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

• Willing to adhere to the prohibitions and restrictions specified in this protocol.

• Patient must signed an informed consent form.

Exclusion Criteria:

• Previous participation in a clinical study of IV or oral rigosertib.

• Anemia due to factors other than MDS (including hemolysis or gastrointestinal [GI] bleeding) unless stabilized for 1 week after RBC transfusion.

• Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.

• Uncontrolled intercurrent illness including.

• Active infection not adequately responding to appropriate therapy.

• Total bilirubin = 1.5 mg/dL not related to hemolysis or Gilbert's disease.

• ALT/AST = 2.5 x upper limit of normal (ULN).

• Serum creatinine = 2.0 mg/dL.

• Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 mEq/L).

• Female patients who are pregnant or lactating.

• Patients who are unwilling to follow strict contraception requirements.

• Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (ßHCG) pregnancy test at Screening.

• Major surgery without full recovery or major surgery within 3 weeks of Baseline/Cycle 1 Day 1 visit.

• Uncontrolled hypertension (defined as a systolic pressure =160 mmHg and/or a diastolic pressure = 110 mmHg).

• New onset seizures (within 3 months prior to Baseline) or poorly controlled seizures.

• Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy.

• Prior treatment with low-dose cytarabine during the past 2 years.

• Investigational therapy within 4 weeks of Baseline/Day 1 visit.

• Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.

Related Conditions & MeSH terms

• Anemia, Refractory, with Excess of Blasts
• Chronic Myelomonocytic Leukemia
• Cytopenia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes
• Preleukemia
• Refractory Anemia With Excess Blasts

Intervention

Drug:
• rigosertib sodium

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Monash Health, Monash Medical Centre	Clayton	Victoria
Australia	Peter MacCallum Cancer Center	East Melbourne	Victoria
Australia	Royal Melbourne Hospital	Parkville	Victoria
Denmark	Aarhus University Hospital	Aarhus	Jylland
Denmark	Rigshospitalet, Department of Hematology	Copenhagen	Hovedstaden
France	Institute Paoli Calmettes	Marseille
France	Hôpital Saint-Louis, Service d'Hématologie	Paris	IDF
Germany	University Hospital Carl Guslav Carus	Dresden
Germany	Marien Hospital, Onkologie	Düsseldorf
Germany	Universitätsklinikum Frankfurt, Goethe Universität	Frankfurt	Hessen
Germany	Universitätsmedizin Göttingen	Göttingen
Germany	Universitätsklinikum Köln Klinik I für Innere Medizin	Köln
Germany	Technische Universität München, III. Medizinische Klinik	München
Italy	Azienda Ospedaliero-Universitaria Careggi	Firenze
Italy	AOU Maggiore della Carità, SCUD Ematologia	Novara
Italy	Policlinico Umberto 1, Universita "Sapienza"	Rome
Spain	Hospital Universitário de Salamanca	Salamanca
Sweden	Sahlgrenska University Hospital	Gothenberg	Västra Götalandsregionen
Sweden	Skåne University Hospital,	Lund	Skåne
Sweden	Karolinska University Hospital, Huddinge	Stockholm
United States	Greenbaum Cancer Center University of Maryland	Baltimore	Maryland
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	Rush University Medical Center	Chicago	Illinois
United States	University of Chicago Medicine	Chicago	Illinois
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	University of Texas Southwestern Medical Center-Parkland Hospital	Dallas	Texas
United States	MD Anderson Cancer Center	Houston	Texas
United States	Columbia University Medical Center	New York	New York
United States	Mount Sinai Medical Center	New York	New York
United States	New York Presbyterian Hospital-Weill Cornell Medical College	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	Stanford University Cancer Center	Stanford	California
United States	University of Kansas Cancer Center and Medical Pavilion	Westwood	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Onconova Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Denmark,  France,  Germany,  Italy,  Spain,  Sweden, 

References & Publications (5)

Al-Kali A. Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethyla

Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res. 2012 Aug;36(8):982-9. doi: 10.1016/j.leukres.2012.04.002. Epub 2012 Apr 21. — View Citation

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14. — View Citation

Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015 Jun;33(2):57-66. doi: 10.1002/hon.2137. Epub 2014 Apr 29. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relationship of bone marrow blast response and overall survival.	Bone marrow blast response is defined as bone marrow (BM) complete response, = 50% BM blast decrease from pretreatment value, or stable BM response (no progression) according to the International Working Group (IWG) 2006 criteria and overall survival. Overall survival is defined as the time from first study treatment to death from any cause. All patients will be followed until death and/or progression, even if they have discontinued treatment for whatever cause. Survival time of patients lost to follow-up will be censored at the time they were last known to be alive.	Up to 2 years.
Secondary	Number of patients with overall hematologic response.	Overall hematologic response (complete remission [CR], partial remission [PR], bone marrow complete response [BMCR], and stable disease [SD]) is defined according to 2006 International Working Group (IWG) response criteria.	Up to 2 years after study enrollment.
Secondary	Number of patients with hematological improvement.	Hematological improvement (erythroid response, platelet response and neutrophil response) is defined according to 2006 International Working Group (IWG) response criteria.	Up to 2 years after study enrollment.
Secondary	Number of patients with cytogenetic response.	Cytogenetic response is defined according to 2006 International Working Group (IWG) response criteria.	Up to 2 years after study enrollment.
Secondary	Progression-free survival.	Progression-free survival is defined as time from date of first dose until date when progression is documented. Progression is defined according to 2006 International Working Group (IWG) response criteria.	Up to 2 years after study enrollment.
Secondary	Number of patients who transition to Acute Myeloid Leukemia (AML)	Participants who progress to Acute Myeloid Leukemia (AML) during the study. AML is defined as an increase of at least 50% bone marrow blasts, and more than 20% bone marrow blasts for Refractory Anemia with Excess Blasts types 1 and 2 (RAEB-1 and RAEB-2) and Chronic Myelomonocytic Leukemia (CMML) patients and as an increase of at least 50% bone marrow blasts for Refractory Anemia with Excess Blasts in Transformation (RAEB-t) patients.	Up to 2 years after study enrollment.
Secondary	Quality of Life Questionnaire	Change from baseline in responses in the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30 version 3. Questionnaire will be administered at baseline and at 4 week intervals.	Up to 2 years after study enrollment.
Secondary	Infections.	Incidence of infections requiring treatment with intravenous antimicrobials and of bleeding episodes.	Up to 2 years after study enrollment.
Secondary	Concentration of rigosertib in plasma.	Concentration of rigosertib in plasma will be measured by a validated High Performance Liquid Chromatography (HPLC) method.	Week 1 and week 3.
Secondary	Safety.	Counts of patients who have adverse events (AEs). Adverse events will be grouped by system organ class (SOC) and preferred term (PT) using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA), and will be summarized by worst grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.	Study enrollment until 30 days after patient's last dose of rigosertib up to 2 years.